Topic Listing for Innoviva, Inc.

A10 Notification Approval Deviations A11 Customer Quality Representatives
A11 Release Shipment Product A12 Bvl Quality Representatives
A12 Retained Samples Product A13 Bvl Business Representative
A13 Storage Product A14 On-call Customer Representative
A14 Stability Activities A15 Process Validation
A16 Product Complaints A17 Returned Goods
A18 Recall Marketed Product A19 Audits Inspections Facilities Product
A20 Reprocessing A22 Annual Quality Agreement Review
A31 A32
A321 A322
A323 A324
A41 Master Production Records A42 Specification
A43 Packaging Labeling Specifications A44 Product Changeover
A45 Changes Plant Acceleration
Acceleration Options Awards Acceleration Put Insolvency Event
Accepting Stock Option Grant Agree Terms Conditions Described Accomplishments Continuing Theravances Discovery Development Medicines Improve Patients
Accumulation Period Accumulation Periods
Addendum International Participants Additional Plan Information
Additional Shares Addresses Including Zip Code Telephone Numbers Area Principal
Adjustments Administration
Administration Plan Adopted
Adopted Fin Effective 2007 Adoption Did Not Result Affiliate
After 2008 Gsk Sell Transfer Substantial Number Shares After 2012 Gsk Sell Transfer Substantial Number Shares
After Ipo After Withdrawal
Agonist Maba Development Status Agreement General Release
Agreement Vote Agreements Glaxosmithkline
Agreements Gsk Agreements Related Board Directors
Amended Restated Investors Rights Agreement Amendment Discontinuance
Amendment Offer Letter Dated 2007 Amendment Restated Certificate Incorporation Enable Issue Class Common
Amendment Termination Amendments
Amendments Articles Incorporation Bylaws Change Amendments Changes Modifications Waivers Agreement Effective Unless Writing
Amendments Termination Amendments Waiver Provision
Amex Biotechnology Index Amount Payroll Deductions
Analysis Populations Anesthesia
Annual Incentive Compensation Annual Product Reviews Reports
Anti-dilution Adjustments Anti-takeover Effects Delaware Law Certificate Incorporation Bylaw Provisions
Anti-takeover Provisions Charter Bylaws Rights Agreement Delaware Law Appendix
Applicable Offering Period Apply Expertise Multivalency Primarily Validated Targets Efficiently Discover
Approval 2004 Equity Incentive Plan Approval Amendment Employee Stock Purchase Plan
Approval Amendment Theravance Inc 2004 Equity Incentive Plan Approval Majority Gsk Nominated Directors Certain Actions
Approval Majority Independent Directors Certain Actions Approved Telavancin Not Accepted Physicians Patients Party Payors
Arnold Levine Arthur Campbell
Assignment Astellas
Asthma Chronic Obstructive Pulmonary Disease Copd Attain Studies
Audit Committee Audit Committee Financial Expert
Audit Committee Pre-approval Policy Audits
Audits Theravance Inc Authorization Agreement Been Duly Authorized Executed Delivered
Authorization Issuance Class Common Stock Call Put Authorization Securities Been Duly Authorized Closing Time Executed
Authorized Number Directors Authorized Shares
Available Information Available Per
Available Shares Insufficient Award
Awards Other Plans Awards Restricted Stock
Awards Stock Units Background
Bacterial Infections Bacterial Infections Program
Bacterial Infections Programs Base
Base Salaries Base Salary
Basic Limitation Basic Rule
Basis Presentation Basis Presentation Employee Stock-based Compensation
Basis Presentation Significant Accounting Policies Batch Rejections
Ben Venue Laboratories Inc Beneficial Owner Shares Registered Name Broker Bank
Beneficial Ownership Reporting Compliance Beyond Advair
Beyond Advair Collaboration Beyond Advair Collaboration Gsk
Beyond Advair Status Biddle Sawyer Pharma Llc
Bifunctional Muscarinic Antagonist-beta Bifunctional Muscarinic Antagonist-beta Agonist Maba
Bifunctional Muscarinic Antagonist-beta Agonist Mabas Copd Possibly Asthma Board
Board Directors Board Directors Recommends Vote Favor Proposal
Board Directors Stockholders Theravance Inc Bona Fide
Bonus Accruals Bonus Program
Bonus Programs Bradford Shafer
Bradford Shafer Senior Vice President General Counsel Secretary Business Operations Suffer Event System Failures
Buyout Provisions C-1
Calculation Registration Fee Call Rights
Cancellation Postponement Capital Lease Arrangements
Capitalized Software Case Offering Period Plan Price Share Stock Offered
Cash Bonus Program Cash Bonus Program Amended Effective 2007
Cash Equivalents Cash Flows
Cautionary Statement Regarding Forward-looking Statements Ceo
Ceo Compensation Ceo Severance
Certain Relationships Related Transactions Director Independence Certification Chief Executive Officer Pursuant 302 Sarbanes-oxley
Certification Chief Executive Officer Pursuant 302 Sarbanes-oxley Act Certification Chief Executive Officer Pursuant Usc 1350 Adopted
Certification Chief Financial Officer Pursuant 302 Sarbanes-oxley Certification Chief Financial Officer Pursuant 302 Sarbanes-oxley Act
Certification Chief Financial Officer Pursuant Usc 1350 Adopted Chairman Board Shall Preside Meetings
Change Control Change Control Severance Benefits
Change Employment Status Change Vote After Submitting Proxy
Changes Capitalization Changes Internal Control Over Financial Reporting
Changes Internal Controls Over Financial Reporting Changing Withholding Rate
Class Common Stock Code
Code Business Conduct Code Ethics
Collaboration Agreements Collaboration Arrangements
Collaboration Licensing Collaboration Licensing Agreements
Commencement Payroll Deductions Commissions Discounts
Commitments Commitments Contingencies
Committee Composition Committee Non-officer Grants
Committee Responsibilities Committees
Common Stock Common Stock 001 Par Value
Common Stock Call Put Arrangements Gsk Comparable National News Service Document Publicly Filed Corporation
Comparison Cumulative Total Return Compensation
Compensation Committee Compensation Committee Interlocks Insider Participation
Compensation Committee Report Compensation Consultant
Compensation Directors Compensation Discussion Analysis
Compensation Executive Officers Compensation Philosophy Objectives
Competition Complaint Adverse Event Handling
Complaints Composition Board Directors
Comprehensive Income Loss Comprehensive Loss
Concentration Credit Risks Other Uncertainties Concentration Ownership Limit Ability Influence Corporate Matters
Conclusions Conditions Receive Severance Payments Change Control Plan
Conditions Severance Payments Conduct Meeting
Conference Call Webcast Information Confidentiality
Consent Independent Registered Public Accounting Firm Consultant
Consulting Agreement Contact Information
Continue Pleased Progress Lead Programs Telavancin Beyond Advair Contractor Operations
Contractual Obligations Commitments Control Documents Change Implementation
Controls Procedures Convertible Preferred Stock
Convertible Subordinated Notes Corporate Opportunities
Corporate Reorganization Corporate Transaction
Corporation Shall Begin End Thirty-first Each Costs Associated Exit Disposal Activities
Creation Direct Financial Obligation Off-balance Sheet Arrangement Creditors Rights
Critical Accounting Policies Critical Accounting Policies Estimates
Current Report Pursuant Securities Exchange Act 1934 Data Increase Confidence Horizon Development Programme
David Brinkley Death
Death Recipient Deferral Awards
Deferred Rent Deferred Stock-based Compensation
Deferred Sublease Costs Definitions
Delegation Authority Delivery Documents Stockholders Sharing Address
Demand Registration Rights Departure Directors
Departure Directors Certain Officers Election Appointment Compensatory Departure Directors Principal Officers Election Appointment
Depend Parties Conduct Clinical Studies Product Candidates Dependent Third-party Vendors Clinical Research Organizations Selected Manufacturing
Description Mathai Mammen Long-term Cash Bonus Arrangement Description Operations Principles Consolidation
Development Programs Deviations Failure Investigations
Director Compensation Director Compensation Program
Directors Executive Officers Corporate Governance Discontinuing Payroll Deductions
Discretionary Discretionary Bonuses
Disposition Baseline Demographic Characteristics Disposition Materials
Disposition Outcomes Dissolution Liquidation
Dividend Equivalents Dividend Equivalents Not Paid Shall Subject Same Conditions
Dividend Policy Dividends
Document Reserve Sample Retention Document Supersedes Other Documents Agreements
Documentation Retention Documents Incorporated Reference
Dollar Limit Dtc Cooperate Underwriter Permit Offered Securities Eligible Clearance
Duration Participation Each Participant Shall Deemed Own Stock She Right
Education Effect Change Control
Effect Headings Herein Convenience Only Shall Not Affect Effect Recent Accounting Pronouncements
Effective Date Effectiveness Amendment
Efforts Protect Proprietary Nature Intellectual Property Related Technologies Election Director
Election Directors Elections Receive Nsos Restricted Shares Stock Units
Eligibility Eligible Employee
Eligible Executive Employment Involuntarily Terminated Within Before Twenty-four Employee
Employee Agrees Modifications Material Otherwise Agreement General Release Employee Contributions
Employee Hereby Waives Provisions 1542 California Civil Code Employee Stock Purchase Plan
Employees Employment
Employment Agreements Encourage Take Advantage Internet Telephone Voting Available
Encourage Take Advantage Internet Telephonic Voting Available Enquiries
Enrollment Enrollment After Ipo
Enrollment Ipo Enrollment Participation
Entry Material Agreement Entry Material Definitive Agreement
Equity Equity Acceleration
Equity Acceleration Change Control Equity Compensation Plan Information
Equity Compensation Plans Equity Incentive Plan
Equity Incentive Plans Evaluation Disclosure Controls Procedures
Eve Slater Even Product Candidates Receive Regulatory Approval Commercialization Such
Even Product Candidates Receive Regulatory Approval Such Vibativ Exactly Shares Common Stock Options Subject Put
Exceptions Agreement Vote Executive Compensation
Executive Officers Executive Summary
Exercisability Term Exercise Pledge
Exercise Price Exercise Sale
Exercise Sars Exhibits
Experience Selling Distributing Products Internal Capability Explanatory
Facc Joined Face Substantial Competition Companies Resources Experience Result Others
Facilities Factors Affecting Results Including Risks Uncertainties
Fail Obtain Capital Necessary Fund Operations Unable Develop Failure Comply Internal Control Attestation Requirements Lead Loss
Failure Delay Commencing Completing Clinical Studies Product Candidates Failure Product Candidate Clinical Studies Delay Commencing Completing
Fair Market Value Fair Market Value Means Price Stock Determined Committee
Fair Market Value Such Share Last Trading Accumulation Fair Value Employee Stock Options
Fair Value Financial Instruments Fair Value Measurements
Fair Value Share-based Payment Awards Fda Not Approve Progression Horizon Program Phase Asthma
Federal Income Tax Consequences Options Granted Incentive Plan Fin Unrecognized Tax Benefits
Financial Results Financial Statements Exhibits
Financial Update Find Out Results Voting Annual Meeting
Finished Product Testing Following Workforce Reduction Lose Key Management Scientific Personnel
Forecast Planning Foregoing Provisions Applicable Then Committee Shall Determine Fair
Form 10-k Form 10-k Annual Report
Form 10-q Form S-3 Registration Statement Securities Act 1933
Form Time Settlement Stock Units Forward-looking Statements
Future Plan Gastrointestinal Motility Dysfunction
Gastrointestinal Motility Dysfunction Program Gateway Boulevard
Gateway Boulevard South San Francisco Gateway Boulevard South San Francisco California 94080
Gateway Boulevard South San Francisco California 94080 650 General
General Administrative General Administrative Expenses
General Compensation Policy General Consequences Disposing Common Stock
General Consequences Owning Common Stock General Rule
Generally George Whitesides
Glaxosmithkline Global Financial Crisis Impact Business Condition Ways Currently
Global Financial Economic Conditions Had Impact Industry Adversely Global Financial Economic Crises Had Impact Industry Adversely
Goal Motility Program Develop Once-a-day Oral Medicine Effective Golden Parachute Tax Limitation
Governance Agreement Governance Agreement Gsk Limits Ability Raise Debt Equity
Governing Law Government Regulation
Government Restrictions Pricing Reimbursement Well Other Healthcare Payor Grant Proxy
Grants Plan-based Awards Gregory Sturmer
Group Insurance Coverage Gsk Approval Certain Issuances Equity Securities
Gsk Beyond Advair Collaboration Gsk Cautionary Statement Regarding Forward-looking Statements
Gsk Not Satisfy Obligations Agreements Them Unable Develop Gsk Sell Transfer Substantial Number Shares Common Stock
Gsk Share Ownership Put Call Rights Gsk Theravance Announce Positive Phase
Gsk Transactions Gsks Ownership Significant Percentage Stock Ability Acquire Additional
Gsks Ownership Significant Percentage Stock Right Membership Board Gsks Ownership Voting Stock Between 351 501 Interim
Gsks Ownership Voting Stock Less 501 Gsks Right Become Controlling Stockholder Membership Board Directors
Gsks Rights Strategic Alliance Governance Agreements Deter Prevent Guarantees Indemnifications
Hazardous Biological Materials Manner Causes Injury Violates Applicable Health Care Benefits
Held 2005 Held 2006
Held 2007 Held 2008
Held 2009 Heterodimer
Heterodimer Status Horizon
Horizon Collaboration Horizon Formerly Referred Beyond Advair Development Status
Horizon Program Horizon Program Gsk
Horizon Programme Horizon Status
Http Irtheravancecom Http Wwwproxyvotecom
Icense Agreement Astrazeneca Identify Structurally Different Product Candidates Each Therapeutic Program
Impact Purchase Price Impairment Long-lived Assets
Improve Expand Protect Technical Capabilities Incentive Plan Amendments Termination
Incentive Stock Options Income Taxes
Incurred Operating Losses Each Since Inception Expect Continue Indemnification
Indemnification Agreements Indemnification Gsk
Indemnification Officers Directors Indenture
Independence Assessment Audit Committee Independence Board Directors
Independent Auditors Independent Registered Public Accounting Firms Fees
Index Information Regarding Board Directors Committees
Information Reporting Backup Withholding Inhaled Bifunctional Muscarinic Antagonist-beta Agonist Maba Program
Inhaled Bifunctional Muscarinic Antagonist-beta2 Agonist Maba Program Inhaled Long Acting Muscarinic Antagonist Lama Program
Inhaled Long-acting Muscarinic Antagonist Lama Bifunctional Antagonist-beta Agonist Inhaled Long-acting Muscarinic Antagonist Lama Program
Inhaled Long-acting Muscarinic Antagonists Lamas Copd Initial Public Offering
Initial Results Demonstrate Potential 444 Treatment Patients Moderate Inspectors Elections Opening Closing Polls
Instruments Requiring Authorized Board Directors Chairman President Attest Insurance Liability Limits
Interest Expense Interest Other Expense
Interest Other Expense Net Interest Other Income
Interest Other Income Net Interest Receivable Related Notes Was Approximately
Interim Financial Information Interim Financial Statements
Internal Control-integrated Framework Internet Telephonic Vote Authorizes Named Proxies Shares Same
Introduction Inventory
Investigations Studies Outside Advisors Ipo
Issuance Common Stock Dividends Issuance Stock
Issuer Purchases Equity Securities Jeffrey Drazan
Julian Baker Label Copy Approval
Lama Status Leave Absence
Legal Proceedings Legal Services
Legend Level Inputs
Leverage Extensive Experience People License Agreement Astrazeneca
License Development Commercialization Agreement License Development Commercialization Agreement Astellas
Limit Number Elections Limitation Acquisition Equity Securities Gsk
Limitation Disposition Equity Securities Gsk Limitation Payments
Limitation Rights Limitations
Limitations Actions Limitations Disposition Equity Securities Gsk
Limitations Dispositions Equity Securities Gsk Limitations Effectiveness Controls
Limitations Exceptions Gsks Rights Acquire Securities Limitations Indebtedness
Limitations Stock Ownership Line Credit
Liquidation Liquidity Capital Resources
List Subsidiaries Litigation Third-party Claims Intellectual Property Infringement Require Divert
Loans Directors Executive Officers Long Acting Muscarinic Antagonist Lama
Long-acting Beta Agonists Labas Treatment Asthma Copd Long-acting Muscarinic Antagonist Lama
Long-acting Muscarinic Antagonist Lama Bifunctional Antagonist-beta Agonist Maba Long-acting Muscarinic Antagonist Lama Development Status
Long-term Long-term Cash Bonus Arrangement
Long-term Incentive Compensation Long-term Obligations
Lose Key Management Scientific Personnel Fail Retain Employees Lose Key Scientists Management Personnel Fail Recruit Additional
Lose Relationships Contract Research Organizations Drug Development Efforts Maba Respiratory Program Treatment Copd
Maba Status Major Exclusion Criteria
Major Inclusion Criteria Majority Directors Present Meeting Quorum Shall Act Board
Managements Estimates Managements Report Internal Control Over Financial Reporting
Mandatory Deferral Payments Manufacturing
Manufacturing Packaging Product Market Price Common Stock Not Guaranteed Adversely Affected
Market Registrants Common Equity Related Stockholder Matters Issuer Marketable Securities
Marty Glick Material Agreement
Material Modification Rights Security Holders Materials
Materials Documentation Means Theravance Inc Delaware Corporation
Meetings Meetings Board Directors
Membership Methods
Michael Aguiar Michael Kitt
Michael Mullen Microbiological Evaluations
Mild Asthmatic Population Minutes
Miscellaneous Moderate Asthmatic Population
Modification Assumption Options Modification Assumption Sars
Multivalency Nda Field Alerts
Net Exercise Net Loss Per Share
New Employee Equity Incentive Plan New Espp Benefits
New Hire Award Committee New Plan Benefits Option Grant Table
Nominating Corporate Governance Committee Nominees
Non-statutory Options Not
Notes Payable Notes Receivable
Notice Restricted Stock Unit Award Notice Stock Option Grant
Notice Stockholder Business Nominations Notices
Notification Put Right Holders Common Stock Theravance Inc Now Access Bny Mellon Shareowner Service Account Online
Now Therefore Nso
Number Elections Number Shares
Number Shares Purchased Number Terms Nsos Restricted Shares Stock Units
Obligations Obligations Gsk
Offering Period Offering Periods
Officers Offices Records
Operating Leases Subleases Option
Option Exercises Stock Ested Option Exercises Stock Vested
Optional Conversion Class Common Stock Options
Orizon Program Gsk Other
Other Atters Other Events
Other Expenses Issuance Distribution Other Forms Payment
Other Grants Other Important Information
Other Information Other Matters
Other Responsibilities Authority Other Stock-based Compensation
Other-than-temporary Impairment Assessment Outcomes
Outside Director Overactive Bladder
Overallotment Option Overpayments Underpayments
Overview Parent
Participant Participating
Participation Partner Global Pharmaceutical Companies
Partners Not Satisfy Obligations Agreements Them They Terminate Partners Not Satisfy Obligations Agreements Them Unable Develop
Patents Proprietary Rights Patients
Patrick Humphrey Payable
Paying Proxy Solicitation Payment Awards
Payment Fees Securities Payment Option Shares
Payment Pricing Payment Procedure
Payment Purchase Price Payroll Deductions Payroll Deductions
Peer Group Percent Limit
Performance Criteria Restricted Shares Stock Units Performance-contingent Restricted Stock Unit Awards
Periods Permitted Gsk Purchases Equity Securities
Permitted Gsk Purchases Equity Securities Stockholders Perquisites
Phase Piggyback Registration Rights
Plan Plan Account
Plan Accounts Plan Accounts Purchase Shares
Please Print Typewrite Name Address Including Zip Code Please Sign Name Appears Hereon Joint Owners Each
Post-termination Protection Pre-approval Policies Procedures
Preclinical Study Clinical Expenses Predecessor Plans
Preferred Stock Price Exercisability
Price Securities Been Extremely Volatile Continue Purchasers Incur Price Securities Extremely Volatile Purchasers Incur Substantial Losses
Price Stabilization Short Positions Principal Accounting Fees Services
Principal Elements Compensation Principal Facility Located Near Known Earthquake Fault Zones
Pro Forma Information Sfas 123 Periods Prior 2006 Proceeds Registered Securities
Processes Controls Risk Management Product Candidates Determined Unsafe Ineffective Humans Not Receive
Product Candidates Develop Own Through Collaborative Partners Not Product Candidates Including Telavancin Currently Phase Clinical Studies
Product Candidates Particular Telavancin Currently Phase Clinical Studies Product Candidates Particular Telavancin Determined Unsafe Ineffective Humans
Product Candidates Particular Telavancin Lead Compounds Horizon Program Product Liability Lawsuits Divert Resources Result Substantial Liabilities
Product Specification Program Design
Program Highlights Programs
Promissory Properties
Property Equipment Proration Purchase Rights
Protection Against Dilution Proxy Solicited Behalf Board Directors
Proxy Solicited Board Directors Proxy Statement Available Http Irtheravancecom Proxycfm
Purchase Obligations Purchase Orders
Purchase Price Purchased Plan Securities Broker Lender Approved Corporation Security
Purchases Equity Securities Issuer Affiliated Purchasers Purpose
Purpose Plan Purpose Term Quality Agreement
Pursuant 302 Sarbanes-oxley Act 2002 Put Rights
Put Shares Put Unexercised Stock Options Cover Puttable Shares
Quality Agreement Quality Responsibilities
Quantitative Qualitative Disclosure Market Risk Quantitative Qualitative Disclosures Market Risk
Quarterly Consolidated Results Operations Ratification Selection Independent Registered Public Accounting Firm
Raw Material Packaging Component Testing Vendor Audit Materials Re-enrollment After Withdrawal
Recalls Receiving Materials
Recent 2003 Medicare Prescription Drug Coverage Legislation Future Recent Accounting Pronouncements
Recent Highlights Recent Medicare Prescription Drug Coverage Legislation Future Legislative
Recent Workforce Changes Recitals
Reclassification Prior Amounts Reclassification Prior Period Amounts
Reclassifications Recognized Revenue 2006 Respectively
Redeemed Shares Redemption Common Stock
Reduction Payments References
Regard Programs Delay Commencing Completing Clinical Studies Product Registration Rights
Regular Meetings Board Directors Resolution Provide Time Place Regulation Disclosure
Regulatory Regulatory Contacts
Regulatory Requirements Related Corporations
Related Parties Related Party Transaction
Related Party Transactions Related Person Ransactions
Related Person Transactions Relationship Glaxosmithkline
Relationship Gsk Negative Effect Ability Enter Relationships Parties Release Commencement Payments
Release Sale Distribution Relied Single Manufacturer Supply Telavancin Continue Rely Limited
Rely Number Manufacturers Product Candidates Business Seriously Harmed Rely Number Manufacturers Product Candidates Single Manufacturer Supply
Rely Single Manufacturer Supply Telavancin Limited Number Manufacturers Rely Single Manufacturer Supply Telavancin Number Manufacturers Other
Reorganizations Report Audit Committee
Report Audit Committee Board Directors Report Compensation Committee
Report Compensation Committee Board Directors Report Independent Registered Public Accounting Firm
Report Independent Registered Public Accounting Firm Consolidated Financial Reported Closing Price Common Shares Nasdaq Global
Reports Representations
Requires Research Development
Research Development Costs Research Development Expenses
Research Programs Reserved Shares
Respiratory Respiratory Programs
Responsibilities Restart Affect Manner Original Forty-five Calendar Consideration Period
Restricted Shares Restricted Stock
Restricted Stock Agreement Restricted Stock Awards
Restricted Stock Unit Agreement Restricted Stock Unit Award Details
Restructuring Charges Results
Results Operations Results Operations Financial Condition
Retention Rights Retention Samples
Revenue Revenue Recognition
Reverse Stock Split Review Approval Ratification Transactions Related Persons
Rick Winningham Rights Agreement
Rights Employee Rights Not Transferable
Rights Stockholder Risks Related Alliance Gsk
Risks Related Business Risks Related Gsks Ownership Stock
Robert Gunderson Ronn Loewenthal
Roy Vagelos S-3 Registration Rights
Safety Salary Non-equity Incentive Plan Compensation Proportion Total
Sale Common Stock Sale Delivery Underwriters Closing
Sales Similar Securities Sar Agreement
Sarbanes-oxley Act 2002 Sars Such Award Provide Options Not Exercisable Unless
Schedule 14a Schedule Shares Reserved Issuance Plan
Science Technology Advisory Committee Scinopharm Taiwan Ltd
Scope Limitation Sec
Sec Reports Other Disclosure Securities Law Requirements
Securities Subject Espp Securities Subject Incentive Plan
Security Ownership Certain Beneficial Owners Management Related Stockholder See Accompanying Notes Condensed Consolidated Financial Statements
Segment Reporting Senior Vice President General Counsel Secretary
Separation Service Service Consultant Shall Considered Employment Purposes Plan Except
Severance Arrangements Severance Cash Payments
Severance Change Control Arrangements Severance Guidelines
Severe Asthmatic Population Share Withholding
Share-based Payments Shares Available Grants
Shares Returned Reserve Shares Subject Substituted Options
She Been Employee Participating Such Period Committee Determine Signature
Signatures South San Francisco 2005
South San Francisco 2006 South San Francisco 2007
South San Francisco 2008 South San Francisco California 94080
South San Francisco California 94080 650 808-6000 Special Regarding Forward-looking Statements
Special Retention Awards Stability
Stability Program Stabilization Manipulation Price Security Facilitate Sale Resale Securities
Staph Aureus Staphylococcus Aureus
Statement Cash Flows Statement Erisa Rights
Statistics Status
Status Development Program Status Program
Stock Appreciation Rights Stock Certificates Transfers
Stock Issuances Stock Means Common
Stock Offered Plan Stock Option Agreement
Stock Option Committee Stock Option Plans
Stock Options Exercised Early Stock Performance Graph
Stock Price Extremely Volatile Purchasers Common Incur Substantial Stock Subject Repurchase
Stock Unit Stock Unit Agreement
Stock Units Stock-based Compensation
Stockholder Approval Stockholder Communications Board Directors
Stockholder Proposals 2006 Stockholder Proposals Due Next Annual Meeting
Stockholder Record Shares Registered Name Stockholders
Stockholders Equity Stockholders Record Shares Registered Name
Stockholders Rights Storage
Strategic Alliance Strategic Alliance Gsk
Strategy Structure
Study Design Study Design Results
Study End Points Subject Federal State Examination 1996 Forward Virtue Tax
Submission Matters Vote Security Holders Subordinated Convertible Notes Due 2015
Subsequent Event Subsequent Events
Subsidiary Substantial Sales Common Stock Price Decline
Such Delegation Power Shall Not Relieve Officer Responsibility Such Individuals Involuntary Dismissal Discharge Corporation Reasons Other
Such Solicitation Notice Shall Set Forth Summary
Summary Compensation Summary Federal Income Tax Consequences
Summary In-window Vital Status Safety Population Summary Put
Surrender Stock Table Contents
Tax Tax Deductibility Pay
Tax Gross-up Tax Limitation
Tax Withholding Td-1792
Td-1792 Development Status Td-1792 Status
Td-4208 Lama Program Td-5108 Development Status
Td-5108 Status Telavancin
Telavancin Collaboration Telavancin Development Status
Telavancin Not Approved Regulatory Agencies Including Food Drug Telavancin Not Approved Treatment Nosocomial Pneumonia Regulatory Agencies
Telavancin Other Product Candidates Develop Own Through Collaborative Telavancin Relationship Astellas
Telavancin Status Term Plan
Term Termination Termination Agreement
Termination Change Payroll Deductions Termination Employment
Termination Service Terms Conditions Described Above Plan
Terms Conditions Manufacture Products Ben Venue Laboratories Inc Testing Product
Text Amendments Bylaws Theravance Inc Text Proposed Amendment
Theravance Theravance Forward-looking Statements
Theravance Inc Theravance Inc 2004 Equity Incentive Plan Notice Restricted
Theravance Inc 2004 Equity Incentive Plan Notice Stock Theravance Inc 901 Gateway Boulevard South San Francisco
Theravance Inc Amended Restated Change Control Severance Plan Theravance Inc Ben Venue Laboratories
Theravance Inc Enquiries Time Shall Essence Agreement Except Otherwise Set Forth
Tments Today
Transfer Agent Registrar Ufficient
Unable Enter Future Collaboration Arrangements Such Collaborations Parties Uncertain Tax Positions
Uncertainty Regarding Effects Recent Health Care Reform Measures Underwriters Not Provided Legal Accounting Regulatory Tax Advice
Unregistered Sales Equity Securities Unregistered Sales Equity Securities Proceeds
Unused Cash Balances Urchased
Vacancies Board Directors Validation Qualification
Valuation Vesting Acceleration Calculation
Vesting Conditions Vesting Schedule
Vibativ Not Accepted Physicians Patients Party Payors Medical Vote
Vote Annual Meeting Votes
Votes Counted Votes Needed Approve Each Proposal
Voting Arrangements Voting Dividend Rights
Wall Street Journal Warrants
What Happens Hold Stock Book Electronic Form Brokerage What Mean Receive Proxy Card
What Quorum Requirement What Return Proxy Card Not Make Specific Choices
What Voting Whereas
William Waltrip William Young
Withdrawal Withdrawal Plan
Withholding Rate Withholding Taxes
Witness Whereof Wwwtheravancecom
Xvi Xvi Sub-contractors
Xvi Withholding Taxes Xvii
Xvii Restricted Compounds Xviii
Xxv Environmental Laws Except Described Registration Statement General 
Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki